A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound. Oxford University researchers have worked in collaboration with industry leaders NuCana to assess a novel chemotherapy drug derived […]
Cancer therapies have seen great development over the decades. Radiotherapies and chemotherapies have saved countless lives, but the latest arsenal, adoptive cell therapies (ACT), has stirred most excitement. In ACT, cells are processed to enhance their anti-cancer immune effects and injected into the patient. A new study by CiRA Professor Shin Kaneko and colleagues shows […]
In a study published this week in Science, Université de Montreal researchers report key structural and biochemical differences among a class of anti-cancer drugs known as PARP inhibitors. These distinguishing differences were linked to differing capacities of PARP inhibitors to kill cancer cells. The research resolves a long-standing and perplexing quandary over differences between the […]
